尼妥珠单抗联合放射治疗改善老年食管鳞癌患者预后的效果评价
Evaluation of the Effect of Nimotuzumab Combined with Radiotherapy on Improving the Prognosis of Elderly Patients with Esophageal Squamous Cell Carcinoma
王伟 1李苓 1杨森2
作者信息
- 1. 山东省滕州市中心人民医院肿瘤三科,山东 滕州 277599
- 2. 山东省滕州市中心人民医院肿瘤一科,山东 滕州 277599
- 折叠
摘要
目的 探讨尼妥珠单抗联合放射治疗改善老年食管鳞癌患者预后的效果.方法 非随机选取2018年1月—2021年6月滕州市中心人民医院收治的92例老年食管鳞癌患者为研究对象.按治疗方法分为两组,每组46例.对照组给予放射治疗,观察组则联合尼妥珠单抗治疗,比较两组疗效、免疫指标、肿瘤标志物、生存率及不良反应.结果 观察组肿瘤控制率为54.35%(25/46),高于对照组的30.43%(14/46),差异有统计学意义(χ2=5.386,P<0.05).观察组免疫指标水平、肿瘤标志物指标水平优于对照组,差异有统计学意义(P均<0.05).两组不良反应比较,差异无统计学意义(P>0.05).观察组治疗后1、2年生存率均高于对照组,差异有统计学意义(P均<0.05).结论 老年食管鳞癌患者应用尼妥珠单抗联合放射治疗可有助于改善免疫功能,下调肿瘤标志物指标表达水平,延长生存期,且不良反应少.
Abstract
Objective To explore the effect of nimotuzumab combined with radiotherapy on improving the prognosis of elderly patients with esophageal squamous cell carcinoma.Methods Ninety-two cases of elderly esophageal squamous carcinoma patients admitted to Tengzhou Central People's Hospital from January 2018 to June 2021 were non-randomly selected as study subjects.They were divided into two groups according to treatment methods,with 46 cases in each group.The control group was given radiation therapy,while the observation group was combined with nitu-zumab treatment,compared the efficacy,immune indexes,tumor markers,survival rate and adverse reactions of the two groups.Results The tumor control rate of the observation group was 54.35%(25/46),which was higher than 30.43%(14/46)of the control group,and the difference was statistically significant(χ2=5.386,P<0.05).The levels of immune indexes and tumor marker indexes in the observation group were better than those in the control group,and the differences were statistically significant(all P<0.05).There was no statistically significant difference between the two groups in adverse reaction(P>0.05).The survival rate of 1 and 2 years after treatment in the observation group were higher than those of the control group,and the differences were statistically significant(both P<0.05).Conclu-sion The application of nituzumab combined with radiation therapy in elderly patients with esophageal squamous car-cinoma may help to improve the immune function,down-regulate the expression level of tumor marker indexes,pro-long the survival period,and have fewer adverse effects.
关键词
食管鳞癌/尼妥珠单抗/放射治疗/免疫功能/肿瘤标志物Key words
Esophageal squamous cell carcinoma/Nimotuzumab/Radiation therapy/Immune function/Tumor markers引用本文复制引用
出版年
2024
NETL
NSTL
万方数据